Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

This study is ongoing, but not recruiting participants.
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
SCRI Development Innovations, LLC Identifier:
First received: December 8, 2009
Last updated: October 16, 2015
Last verified: October 2015

December 8, 2009
October 16, 2015
March 2010
October 2014   (final data collection date for primary outcome measure)
Complete Response Rate [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Percentage of responses showing complete disappearance of all signs of cancer in response to treatment.
To determine the complete response rate in patients with previously untreated low grade lymphoma following treatment with bendamustine/bortezomib/rituximab. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01029730 on Archive Site
  • Overall Response Rate [ Time Frame: At 3 and 6 months during treatment, then 6 months post-treatment. ] [ Designated as safety issue: No ]
    Defined as the proportion of patients with confirmed complete or partial response (CR or PR) according to Revised Response Criteria for Malignant Lymphoma.
  • Progression-free Survival [ Time Frame: at 3 and 6 months, then every 3 months post-treatment for 1 year and every 6 months thereafter until disease progression; projected 2 years. ] [ Designated as safety issue: No ]
    Defined as the time from first treatment until objective tumor progression or death.
  • Frequency of adverse events and their severity as a measure of safety. [ Time Frame: Days 1,8, and 15 of each 28-day cycle for 6 months, then every 3 months for a year, projected 2 years. ] [ Designated as safety issue: Yes ]
    Toxicity grades will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0.
  • To assess overall response rate (ORR) in patients with previously untreated low grade lymphoma following treatment with bendamustine/bortezomib/rituximab. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To assess progression-free survival (PFS) of patients with previously untreated low grade lymphoma following treatment with bendamustine/bortezomib/rituximab. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To characterize the toxicity of bendamustine/bortezomib/rituximab in patients with previously untreated low grade lymphoma. [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
The goal of this multi-center Phase II study is to add bortezomib to the highly active regimen of bendamustine and rituximab. In this study, bortezomib will be administered on a weekly schedule (Days 1, 8, 15) and will be added to bendamustine/rituximab given in 4-week cycles. This combination uses the standard bendamustine dosing schedule, and is more convenient than the 5-week regimen of these 3 drugs currently being studied.
Not Provided
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Drug: Bendamustine
    Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
    Other Name: TREANDA®
  • Drug: Bortezomib
    Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
    Other Name: VELCADE®
  • Drug: Rituximab
    Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
    Other Name: Rituxan®
Experimental: Bendamustine/Bortezomib/Rituximab
Treatment for all patients will be given in cycles of 28 days (4 weeks). All patients will receive treatment with bendamustine, bortezomib, and rituximab for a maximum of 6 cycles. Rituximab should be administered first.
  • Drug: Bendamustine
  • Drug: Bortezomib
  • Drug: Rituximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
December 2015
October 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histologically-confirmed indolent lymphoma by the World Health Organization (WHO) classification. The biopsy must fulfill one of the following criteria:

    • Follicular lymphoma, grade 1 or 2
    • Marginal zone lymphoma
    • Small lymphocytic lymphoma (circulating lymphocyte count must be <5,000)
    • Lymphoplasmacytic lymphoma
  2. At least one of the following criteria must be met:

    • Presence of any symptoms related to lymphoma. These can include classic B-symptoms (fever [>38°C] of unclear etiology, night sweats, weight loss of greater than 10% within the prior 6 months) or other lymphoma-related symptoms (fatigue, pain, etc.).
    • Large tumor mass (bulky disease) characterized by lymphomas with a diameter of more than 3 cm in three or more regions or by a lymphoma with a diameter >7 cm in one region
    • Presence of lymphoma-related complications, including narrowing of ureters or bile ducts, tumor-related compression of a vital organ, lymphoma-induced pain, cytopenias related to lymphoma/leukemia, splenomegaly, pleural effusions, or ascites
    • Hyperviscosity syndrome due to monoclonal gammopathy
  3. The lymph node biopsy or other lymphoma pathology specimen has CD20+ B-cells.
  4. Ann-Arbor Stage 2 (non-contiguous), 3, or 4 disease.
  5. No previous systemic treatment for lymphoma. Patients may have had a single course of radiation therapy to a limited field (i.e., not exceeding two adjacent lymph node regions).
  6. The patient has bidimensionally measurable disease with at least 1 lesion measuring ≥2.0 cm in a single dimension, and the field was not previously radiated.
  7. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
  8. Adequate hematologic function ≤7 days prior to start of study treatment:

    • Hemoglobin ≥10.0 g/dl
    • Absolute neutrophil count (ANC) ≥1000/µL
    • Platelet count ≥75,000/µL. If low counts are attributable to bone marrow infiltration or hypersplenism due to lymphoma, ANC must be ≥750/µL and platelets ≥50,000/µL.
  9. Calculated or measured creatinine clearance ≥30 mL/min ≤7 days of study enrollment (using Cockcroft-Gault method).
  10. Adequate hepatic function (≤2.5 x upper limit of normal [ULN] for alanine aminotransferase [ALT], aspartate aminotransferase [AST], and alkaline phosphatase and total bilirubin within normal limits).
  11. Patients must be ≥18 years of age.
  12. Women of childbearing potential must agree to use a medically acceptable method of birth control (e.g., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and for 12 months after their last dose of rituximab. Men must use an acceptable method/form of contraception for the duration of treatment and for 3 months after the end of treatment.
  13. Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry.

Exclusion Criteria:

  1. The patient has chronic lymphocytic leukemia.
  2. The patient has transformed lymphoma.
  3. History of, or clinically apparent, central nervous system (CNS) lymphoma or leptomeningeal lymphoma.
  4. The patient has received corticosteroids for treatment of lymphoma. Chronic, low-dose corticosteroids (e.g., prednisone ≤20 mg/day) are allowed for treatment uses other than lymphoma or complications of lymphoma.
  5. Peripheral neuropathy ≥ CTCAE v3.0 grade 2, ≤14 days of study enrollment.
  6. Myocardial infarction ≤6 months prior to study enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, ECG abnormalities at screening must be documented as not medically relevant.
  7. History of solid organ transplantation, or post-transplant lymphoproliferative disorder.
  8. Patients with known history of hepatitis B or hepatitis C infection. Hepatitis B surface antigen must be tested.
  9. The patient has known human immunodeficiency virus (HIV) infection.
  10. Active, clinically serious infection > grade 2. Patients may be eligible upon resolution of the infection.
  11. Female patient is pregnant or breast-feeding. Confirmation that female patients of childbearing potential are not pregnant must be established by a negative serum pregnancy test ≤7 days prior to the start of treatment.
  12. Known hypersensitivity to bendamustine, bortezomib, boron, mannitol, or rituximab.
  13. Concomitant active malignancy requiring therapy.
  14. Diagnosis or treatment for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
  15. Treatment with other investigational agents ≤14 days prior to study enrollment.
  16. Any other disease(s), psychiatric condition, metabolic dysfunction, or findings from a physical examination or clinical laboratory test result that would cause reasonable suspicion of a disease or condition, that contraindicates the use of study drugs, that may increase the risk associated with study participation, that may affect the interpretation of the results, or that would make the patient inappropriate for this study.
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
  • Millennium Pharmaceuticals, Inc.
  • Cephalon
Study Chair: Ian W. Flinn, MD, PhD SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
October 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP